Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Arginine Vasopressin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Gland Pharma receives FDA approval for Vasopressin in 5% Dextrose RTU Injection
Details : Vasopressin is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines.
Product Name : Vasostrict-Generic
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
August 26, 2025
Lead Product(s) : Arginine Vasopressin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Norepinephrine Bitartrate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Gland Pharma gets approval for Norepinephrine Bitartrate in 5% Dextrose injection bags
Details : Norepinephrine Bitartrate in Dextrose Injection is a catecholamine indicated for restoration of blood pressure in adult patients with acute hypotensive states.
Product Name : Norepinephrine Bitartrate-Generic
Product Type : Hormone
Upfront Cash : Inapplicable
August 12, 2025
Lead Product(s) : Norepinephrine Bitartrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cangrelor
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Gland Pharma receives FDA approval for Cangrelor for Injection 50 mg/vial
Details : Kengreal-Generic (cangrelor) is a P2Y12 platelet inhibitor, which is indicated for the treatment of periprocedural myocardial infarction.
Product Name : Kengreal-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 12, 2025
Lead Product(s) : Cangrelor
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Angiotensin II
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Gland Pharma Receives USFDA Approval for Angiotensin II Acetate Injection
Details : Angiotensin II Acetate Injection is a vasoconstrictor indicated for increasing blood pressure in adults experiencing septic or other distributive shock.
Product Name : Giapreza-Generic
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
June 04, 2025
Lead Product(s) : Angiotensin II
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Latanoprostene Bunod
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Gland Pharma receives USFDA approval for Latanoprostene Bunod Ophthalmic Solution
Details : Vyzulta-Generic (latanoprostene bunod) is a prostaglandin analog indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Product Name : Vyzulta-Generic
Product Type : HPAPI
Upfront Cash : Inapplicable
May 01, 2025
Lead Product(s) : Latanoprostene Bunod
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paracetamol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Gland Pharma receives approval for Acetaminophen Injection
Details : Acetaminophen-Generic is a COX inhibitor, small molecule candidate, which is indicated for the management of mild to moderate pain in adult and pediatric patients 2 years and older.
Product Name : Acetaminophen Injection-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 04, 2025
Lead Product(s) : Paracetamol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vitamin K1
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Gland Pharma Receives USFDA Approval for Phytonadione Injectable Emulsion
Details : Phytonadione is indicated for coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
December 11, 2024
Lead Product(s) : Vitamin K1
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Gland Pharma Secures US FDA Approval for Latanoprost Ophthalmic Solution
Details : Xalatan-Generic (latanoprost) is a prostanoid FP receptor agonist, small molecule drug candidate, which is indicated for the treatment of open-angle glaucoma or ocular hypertension
Product Name : Xalatan-Generic
Product Type : HPAPI
Upfront Cash : Inapplicable
December 02, 2024
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Latanoprostene Bunod
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Gland Pharma Receives Tentative FDA Approval for Latanoprostene Solution
Details : Latanoprostene bunod is a prostaglandin analog, which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Product Name : Vyzulta-Generic
Product Type : HPAPI
Upfront Cash : Inapplicable
July 23, 2024
Lead Product(s) : Latanoprostene Bunod
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eribulin
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Gland Pharma Receives USFDA Approval for Eribulin Mesylate Injection
Details : Eribulin Mesylate, a non-taxane microtubule dynamics inhibitor used for the treatment of breast cancer, is expected to be the first generic approval on the market.
Product Name : Eribulin Mesylate-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 07, 2024
Lead Product(s) : Eribulin
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable